




transpara®

Powered by FusionAI™



Transpara in clinical mammography

Transpara in clinical mammography

Transpara is primarily intended to help radiologists in screening mammography. That does not mean, however, that it cannot contribute to the quality of clinical mammography applications. This brochure is intended to highlight where Transpara can be used in clinical mammography and also where one should not rely on Transpara results.

The Transpara algorithms have been designed to detect and characterize suspicious abnormalities in mammograms and tomosynthesis (DBT) images. The images used for training of the algorithms include both clinical and screening exams of predominantly asymptomatic women. Clinical studies demonstrate that stand alone performance of Transpara for the detection of breast cancer matches that of experienced radiologists, and that radiologists improve when they are supported by Transpara.

Clinical studies that formed the basis for regulatory clearance of Transpara were performed with experienced breast radiologists who reviewed enriched series of exams with a mixture of malignant and benign lesions, as well as normals. The clinical reader study settings and data were representative for

screening and for a range of applications in clinical mammography.

It should be noted that the training data used to develop Transpara did not include follow-up exams of patients after breast surgery, while it included relatively few exams in women with symptoms such as palpable lumps, pain, nipple discharge or skin changes. Radiologists should be aware of the limitations of Transpara in clinical applications.


Summary of using Transpara in clinical mammography

APPLICATION	YES / NO	APPLICATION
Diagnostic assessment in women recalled from screening		<p>Improve diagnostic procedure by better assessment of the level of suspicion of regions detected at screening</p> <p>Checking the entire mammogram for presence of other suspicious abnormalities that may not have been seen at screening</p>
Surveillance in high risk population		Similar benefit as in the general screening population
Early detection in asymptomatic women outside regular screening programs		Similar benefit as in the general screening population
Follow up of probably benign abnormal findings		Region scores support assessment of level of suspicion
Diagnosing symptomatic women		Region scores may support assessment of symptomatic cases. Radiologists should be aware of the limitations, especially for abnormality types that occur infrequently
Checking for recurrence after breast surgery		Transpara region scores are unreliable when there are scars, and this task heavily relies on comparison with priors


Always refer to the intended use statement

Examples of using Transpara in clinical mammography

Transpara is a **second pair of eyes** to help identify regions of suspicion in every image and every view





This is an illustration of how the Transpara Region Score changes over time as the level of suspicion increases..



In this challenging case, Transpara helped to identify a small 0.6mm non palpable suspicious lesion in the left breast. It was confirmed as an invasive carcinoma via biopsy.

TRANSPARA HELPS to evaluate the suspicious different findings providing objective data in both 2D and 3D mammograms.





In this case, Transpara has an Exam Score of 10 indicating elevated risk.



Transpara correctly identifies 2 masses in the left breast with different region scores: An Invasive Ductal Carcinoma at 12 o'clock and another Invasive Ductal Carcinoma & Ductal Carcinoma In Situ at 10 o'clock.



TRANSPARA HELPS radiologists make more confident decisions



TRANSPARA CAN HELP to identify suspicious calcification clusters



Transpara - the **clinically proven** decision support system



To date, **Transpara** is installed
in clinics in over **25 countries**



Over **1.3 million**
mammograms processed
with **Transpara**



Trained on over **1 million**
images from over **10 countries**



Peer review **published**
scientific evidence



Supporting over 35 ongoing
international **clinical studies**



True **multivendor**
compatibility

FDA cleared and **CE marked** for **2D and 3D mammography**

www.screenpoint-medical.com

SPM-SMR-001-066 1.4

© 2021 ScreenPoint Medical BV. Transpara® is a registered trademark of ScreenPoint Medical BV. Views and opinions expressed herein by third parties are theirs alone and do not necessarily reflect those of ScreenPoint Medical. This information is intended for medical professionals and is not intended as a product solicitation or promotion where such activities are prohibited. Because ScreenPoint Medical materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products and features are available in a particular country, please contact your local representative or write to info@screenpointmed.com

ScreenPoint Medical, Toernooiveld 300, 6525 EC Nijmegen, The Netherlands | Tel: +31 242020020

SCREENPOINT
Medical